Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers

ConditionsMalignant Female Reproductive System Neoplasm Metastatic Malignant Female Reproductive System Neoplasm Unresectable Malignant Female Reproductive System Neoplasm

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18+

SponsorFred Hutchinson Cancer Center

About this trial

This study is being done to determine how easy it is to use standard of care (SOC) surgical resections or biopsy for SmartMatch analysis to determine treatment options in advanced gynecological malignancies.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Histologically confirmed rare gynecologic malignancy, including but not limited to those listed

Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated

Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis

Disqualifiers

Lack of tumor tissue suitable for SmartMatch analysis

Purely borderline tumors or benign ovarian/uterine neoplasms

Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy

Inability to provide informed consent or comply with study procedures

Trial design

Treatments tested in this trial

Not listed

Trial groups

30 Participants

are grouped into 1 trial group

Sponsors and collaborators

Fred Hutchinson Cancer Center

Lead sponsor

Source ClinicalTrials.gov